04.07.26 -- How To Separate AI Hype From Real Value

Victoria Gamerman, strategy leader for RWD Insights, outlines three principles for evaluating AI solutions, including proven experience, data readiness, and lifecycle ownership.

Uncover how you can navigate FDA expectations and Institutional Review Board (IRB) requirements when integrating AI and Software-as-a-Medical-Device into clinical trials.

Digital biomarkers are reshaping clinical research with continuous, real‑world data. Explore how emerging tools, AI, and cross‑industry collaboration are driving smarter clinical development.

Simplify the clinical trial journey by unifying logistics, data, and payments. Reduce administrative friction for sites and improve the patient experience to accelerate trial timelines.

Ditch outdated paper assessments to ensure data integrity. Digital capture improves regulatory compliance, reduces administrative burden, and enhances the patient experience in clinical trials.

Endpoint‑driven studies need platforms that unify wearable data with trial systems, support derived measures, and ensure traceability so continuous data becomes reliable clinical evidence.

Enhance participant retention through intuitive UX and real-time site support tools, while seamlessly integrating with IRT, EDC, and third-party platforms.